NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against RAPT Therapeutics, Inc. ("RAPT" or the "Company") (NASDAQ:RAPT) on behalf of RAPT stockholders. Our investigation concerns whether RAPT has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On February 20, 2024, the Company "announced that the U.S. Food and Drug Administration (FDA) has verbally notified the company that a clinical hold ...